相关实验视频

Updated: Aug 10, 2026

A "Patient-Like" Orthotopic Syngeneic Mouse Model of Hepatocellular Carcinoma Metastasis

A "Patient-Like" Orthotopic Syngeneic Mouse Model of Hepatocellular Carcinoma Metastasis

Published on: October 24, 2015

一个患有肝细胞癌的患者的眼转移性瘤

Takuma Iwai¹, Hiroshi Makino², Hiroshi Yoshida¹

¹Surgery, Nippon Medical School, Tokyo, JPN.

|December 26, 2024

概括

由肝细胞癌 (HCC) 引起的眼球转移或眼球转移是罕见的. 放射治疗有效缓解疼痛,改善了患有这种疾病的患者的生活质量.

科学领域:

在瘤学瘤学.
眼科医生眼科眼科
医疗成像医学成像

背景情况:

肝细胞癌 (HCC) 很少转移到眼睛,乳腺癌和肺癌是较常见的眼球转移的主要来源.
从HCC中记录了轨道地板转移,但转移到眼球本身是非常罕见的.

研究的目的:

在65岁的男性患者中报告罕见的HCC眼转移病例.
讨论诊断和治疗方面的挑战和结果,以管理HCC的眼球转移.

主要方法:

根据成像,该患者被诊断为HCC (cT3N0M0,III期) 患者.
最初的治疗包括胆汁排水,风控制和透气管动脉化学栓塞 (TACE).
眼球转移的诊断是基于底部检查和CT扫描,随后进行放射治疗以缓解症状.

主要成果:

患者出现视力障碍和严重疼痛,表明眼球转移.
辐射疗法提供了显著的疼痛缓解,尽管患者的一般状况不佳,排除了核分裂.
除了眼部的干涉,没有检测到其他远程转移.

结论:

从HCC引起的眼转移虽然很少见,但由于疼痛和视力受损,它可以显著影响生活质量.
辐射疗法是眼球转移的有价值的局部治疗选择,特别是当全身治疗是不可行的,提供快速的症状缓解.

关键词:

眼球转移的转移.肝细胞癌 (hcc) 是一种肝细胞癌.眼球转移是眼球转移.控制疼痛控制疼痛辐射治疗疗法辐射治疗疗法

更多相关视频

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

Non-Invasive PET/MR Imaging in an Orthotopic Mouse Model of Hepatocellular Carcinoma

Non-Invasive PET/MR Imaging in an Orthotopic Mouse Model of Hepatocellular Carcinoma

Published on: August 31, 2022

相关概念视频

The Retinoblastoma Gene

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...